Introduction This analysis examines the historical and forecast performance for Teva in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key branded drugs. An interactive data and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase Identify Tevas diversification strategy into the branded and biosimilar arenas Benchmark Tevas performance against key rivals in the generic pharmaceutical sector Evaluate Tevas historical and forecast, branded and generic growth drivers and resistors
